Prevention of oculopharyngeal muscular dystrophy by muscular expression of Llama single-chain intrabodies in vivo
- PMID: 19258344
- DOI: 10.1093/hmg/ddp101
Prevention of oculopharyngeal muscular dystrophy by muscular expression of Llama single-chain intrabodies in vivo
Abstract
Oculopharyngeal muscular dystrophy (OPMD) is a late onset disorder characterized by progressive weakening of specific muscles. It is caused by short expansions of the N-terminal polyalanine tract in the poly(A) binding protein nuclear 1 (PABPN1), and it belongs to the group of protein aggregation diseases, such as Huntington's, Parkinson's and Alzheimer diseases. Mutant PABPN1 forms nuclear aggregates in diseased muscles in both patients and animal models. Intrabodies are antibodies that are modified to be expressed intracellularly and target specific antigens in subcellular locations. They are commonly generated by artificially linking the variable domains of antibody heavy and light chains. However, natural single-chain antibodies are produced in Camelids and, when engineered, combined the advantages of being single-chain, small sized and very stable. Here, we determine the in vivo efficiency of Llama intrabodies against PABPN1, using the established Drosophila model of OPMD. Among six anti-PABPN1 intrabodies expressed in muscle nuclei, we identify one as a strong suppressor of OPMD muscle degeneration in Drosophila, leading to nearly complete rescue. Expression of this intrabody affects PABPN1 aggregation and restores muscle gene expression. This approach promotes the identification of intrabodies with high therapeutic value and highlights the potential of natural single-chain intrabodies in treating protein aggregation diseases.
Similar articles
-
Prevention of oculopharyngeal muscular dystrophy-associated aggregation of nuclear polyA-binding protein with a single-domain intracellular antibody.Hum Mol Genet. 2006 Jan 1;15(1):105-11. doi: 10.1093/hmg/ddi432. Epub 2005 Nov 30. Hum Mol Genet. 2006. PMID: 16319127
-
Oculopharyngeal muscular dystrophy: potential therapies for an aggregate-associated disorder.Int J Biochem Cell Biol. 2006;38(9):1457-62. doi: 10.1016/j.biocel.2006.01.016. Epub 2006 Feb 28. Int J Biochem Cell Biol. 2006. PMID: 16530457 Review.
-
Structural basis for a PABPN1 aggregation-preventing antibody fragment in OPMD.FEBS Lett. 2010 Apr 16;584(8):1558-64. doi: 10.1016/j.febslet.2010.03.010. Epub 2010 Mar 10. FEBS Lett. 2010. PMID: 20226184
-
Cytoplasmic targeting of mutant poly(A)-binding protein nuclear 1 suppresses protein aggregation and toxicity in oculopharyngeal muscular dystrophy.Traffic. 2005 Sep;6(9):766-79. doi: 10.1111/j.1600-0854.2005.00315.x. Traffic. 2005. PMID: 16101680
-
Progress on gene therapy, cell therapy, and pharmacological strategies toward the treatment of oculopharyngeal muscular dystrophy.Hum Gene Ther. 2015 May;26(5):286-92. doi: 10.1089/hum.2015.014. Epub 2015 May 11. Hum Gene Ther. 2015. PMID: 25860803 Review.
Cited by
-
Mitochondrial dysfunction reveals the role of mRNA poly(A) tail regulation in oculopharyngeal muscular dystrophy pathogenesis.PLoS Genet. 2015 Mar 27;11(3):e1005092. doi: 10.1371/journal.pgen.1005092. eCollection 2015 Mar. PLoS Genet. 2015. PMID: 25816335 Free PMC article.
-
Exploring the Potential of Small Molecule-Based Therapeutic Approaches for Targeting Trinucleotide Repeat Disorders.Mol Neurobiol. 2020 Jan;57(1):566-584. doi: 10.1007/s12035-019-01724-4. Epub 2019 Aug 9. Mol Neurobiol. 2020. PMID: 31399954 Review.
-
Antiprion drugs 6-aminophenanthridine and guanabenz reduce PABPN1 toxicity and aggregation in oculopharyngeal muscular dystrophy.EMBO Mol Med. 2011 Jan;3(1):35-49. doi: 10.1002/emmm.201000109. EMBO Mol Med. 2011. PMID: 21204267 Free PMC article.
-
Design and selection of a camelid single-chain antibody yeast two-hybrid library produced de novo for the cap protein of porcine circovirus type 2 (PCV2).PLoS One. 2013;8(3):e56222. doi: 10.1371/journal.pone.0056222. Epub 2013 Mar 1. PLoS One. 2013. PMID: 23469171 Free PMC article.
-
In vivo detection of amyloid-β deposits using heavy chain antibody fragments in a transgenic mouse model for Alzheimer's disease.PLoS One. 2012;7(6):e38284. doi: 10.1371/journal.pone.0038284. Epub 2012 Jun 4. PLoS One. 2012. PMID: 22675537 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
